fbpx

Day

December 11, 2015
Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Dr. William J. Polvino steps down as President and CEO after more than six years in the role.
93% of patients had full or partial cyst resolution at 12 months. No post-operative infections reported during follow-up period. No fractures reported during the follow-up period

News

Eske Willerslev receives prestigious Norwegian science prize for his Lundbeck Foundation research on brain disorders
22. January 2021
Science Programme Director (Open Neuroplatform)
18. January 2021
Scientific Programme Director (Talent programs)
15. January 2021

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge